BioClinica Partners with Health Sciences International and PRL Central Laboratory Services

BioClinica Partners with Health Sciences International and PRL Central Laboratory Services
New CRO Partnerships Strengthen Its Certified Partner Program 

NEWTOWN, Pa., Mar 04, 2010 (BUSINESS WIRE) -- BioClinica(TM), Inc., a global provider of clinical trial management services, today announced it has created strategic partnerships with two clinical research organizations (CROs), Health Sciences International, Inc., and PRL Central Laboratory Services. Both alliances strengthen the BioClinica Certified Partner Program, a group of VIP CRO partners chosen based on therapeutic expertise and customer satisfaction.

"We are proud to partner with Health Sciences International and PRL Central Laboratory Services, expanding upon the dozens of CRO partnerships held by BioClinica worldwide," said Mark Weinstein, CEO of BioClinica, Inc. "Our newest partners demonstrate the quality and continued growth of the BioClinica Certified Partner Program. To date our certified partners represent a collective experience of more than 700 trials in more than 6,000 sites across 52 countries. This program is one more way that BioClinica provides best-in-class resources for customers."

Connecticut-based Health Sciences International, Inc. focuses on conducting quality phase I-IV trial research with key therapeutic areas of focus including cardiology, vascular disorders, CNS, endocrinology and internal medicine. The organization has participated in more than 100 clinical trials, offering clients consulting services that include R&D expertise, statistical analysis plan development, project and data management, quality enforcement and team building.

PRL Central Laboratory Services specializes in comprehensive diagnostic testing, focusing on protocol requirements. For more than 30 years, the Kansas-based research organization has worked with clinical service providers like BioClinica, ensuring timely results and validated data management for customers.

About BioClinica

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

SOURCE: BioClinica, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.